RxDoctor Payments DataLook up a doctor →

Nilofar Kuraishi, MD

Family Medicine · Las Vegas, NVNPI 1255372280

Payments from drug & device makers

$13,513in general payments, 2019–2025

Across 281 payments — averaging $48.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Amgen$887
  • Novo Nordisk$758
  • Astellas Pharma US Inc$594
  • plus $5K from 46 others

What the payments were for

  • Consulting fees$1,2009%
  • Food & beverage$12,12790%
  • Education$1861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,513 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$32,401
Medicare patients
115
Services billed
410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$46,001
JardianceEmpagliflozin33$36,277
FarxigaDapagliflozin Propanediol12$17,114
JanumetSitagliptin Phos/Metformin Hcl12$13,705
BrilintaTicagrelor17$10,486
Albuterol Sulfate HfaAlbuterol Sulfate110$6,960
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$6,232
Diclofenac Sodium76$5,473
Lidocaine21$3,763
Ibuprofen200$3,465
Gabapentin156$2,926
Atorvastatin Calcium343$2,673
Omeprazole215$2,536
Ventolin HfaAlbuterol Sulfate18$2,353
Metformin Hcl349$2,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$441$46,00136 claims
Boehringer IngelheimJardiance$422$36,27733 claims
AstraZenecaFarxiga, Brilinta$2,532$27,60029 claims
MerckJanumet$32$13,70512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →